Adalimumab induced-inflammatory myopathy in rheumatoid arthritis


Autoria(s): Carlos de Souza, Fernando Henrique; Morais Barros, Thiago Bitar; Levy-Neto, Mauricio; Shinjo, Samuel Katsuyuki
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

31/10/2013

31/10/2013

2012

Resumo

The application of immunobiologics for the rheumatoid arthritis treatment may present as a rare complication the development of inflammatory myopathy. Until this moment, there have been described in literature only seven cases of inhibitors of tumor necrosis factor induced-myositis. In this paper, we report the case of the patient with 39 years-old with eight years of arthritis rheumatoid and that due to refractory to various immunosuppressive drugs, the adalimumab was introduced, and evolved to dermatomyositis status.

Identificador

ACTA REUMATOLOGICA PORTUGUESA, ALGES, v. 37, n. 2, pp. 180-183, APR-JUN, 2012

0303-464X

http://www.producao.usp.br/handle/BDPI/37051

Idioma(s)

por

Publicador

MEDFARMA-EDICOES MEDICAS, LDA

ALGES

Relação

ACTA REUMATOLOGICA PORTUGUESA

Direitos

openAccess

Copyright MEDFARMA-EDICOES MEDICAS, LDA

Palavras-Chave #ADALIMUMAB #DERMATOMYOSITIS #IMMUNOBIOLOGICS #POLYMYOSITIS #ANTISINTETASE SYNDROME #TRANSFER RNA-SYNTHETASE #DERMATOMYOSITIS #AUTOANTIBODIES #MYOSITIS #POLYMYOSITIS #THERAPY #RHEUMATOLOGY
Tipo

article

original article

publishedVersion